Overview of Tumor Heterogeneity in High-Grade Serous Ovarian Cancers

被引:10
|
作者
Azzalini, Eros [1 ]
Stanta, Giorgio [1 ]
Canzonieri, Vincenzo [1 ,2 ]
Bonin, Serena [1 ]
机构
[1] Univ Trieste, Dept Med Sci DSM, I-34149 Trieste, Italy
[2] Aviano Natl Canc Inst, Ctr Riferimento Oncol CRO IRCCS, Pathol Unit, I-33081 Pordenone, Italy
关键词
HGSOC; intratumor heterogeneity; SET; classic; clonal evolution; TME; CIN; PLATINUM RESISTANCE; GERMLINE MUTATION; INVASION PATTERNS; CARCINOMA; REVEALS; MICROENVIRONMENT; CLASSIFICATION; MACROPHAGES; RECURRENCE; MORPHOLOGY;
D O I
10.3390/ijms242015077
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Ovarian cancers encompass a group of neoplasms originating from germinal tissues and exhibiting distinct clinical, pathological, and molecular features. Among these, epithelial ovarian cancers (EOCs) are the most prevalent, comprising five distinct tumor histotypes. Notably, high-grade serous ovarian cancers (HGSOCs) represent the majority, accounting for over 70% of EOC cases. Due to their silent and asymptomatic behavior, HGSOCs are generally diagnosed in advanced stages with an evolved and complex genomic state, characterized by high intratumor heterogeneity (ITH) due to chromosomal instability that distinguishes HGSOCs. Histologically, these cancers exhibit significant morphological diversity both within and between tumors. The histologic patterns associated with solid, endometrioid, and transitional (SET) and classic subtypes of HGSOCs offer prognostic insights and may indicate specific molecular profiles. The evolution of HGSOC from primary to metastasis is typically characterized by clonal ITH, involving shared or divergent mutations in neoplastic sub-clones within primary and metastatic sites. Disease progression and therapy resistance are also influenced by non-clonal ITH, related to interactions with the tumor microenvironment and further genomic changes. Notably, significant alterations occur in nonmalignant cells, including cancer-associated fibroblast and immune cells, during tumor progression. This review provides an overview of the complex nature of HGSOC, encompassing its various aspects of intratumor heterogeneity, histological patterns, and its dynamic evolution during progression and therapy resistance.
引用
收藏
页数:14
相关论文
共 50 条
  • [31] A Complex Network of Tumor Microenvironment in Human High-Grade Serous Ovarian Cancer
    Kreuzinger, Caroline
    Geroldinger, Angelika
    Smeets, Dominiek
    Braicu, Elena Ioana
    Sehouli, Jalid
    Koller, Julia
    Wolf, Andrea
    Darb-Esfahani, Silvia
    Joehrens, Korinna
    Vergote, Ignace
    Vanderstichele, Adriaan
    Boeckx, Bram
    Lambrechts, Diether
    Gabra, Hani
    Wisman, G. Bea A.
    Trillsch, Fabian
    Heinze, Georg
    Horvat, Reinhard
    Polterauer, Stephan
    Berns, Els
    Theillet, Charles
    Castillo-Tong, Dan Cacsire
    CLINICAL CANCER RESEARCH, 2017, 23 (24) : 7621 - 7632
  • [32] Classification of High-Grade Serous Ovarian Cancer Using Tumor Morphologic Characteristics
    Handley, Katelyn F.
    Sims, Travis T.
    Bateman, Nicholas W.
    Glassman, Deanna
    Foster, Katherine, I
    Lee, Sanghoon
    Yao, Jun
    Yao, Hui
    Fellman, Bryan M.
    Liu, Jinsong
    Lu, Zhen
    Conrads, Kelly A.
    Hood, Brian L.
    Barakat, Waleed
    Zhao, Li
    Zhang, Jianhua
    Westin, Shannon N.
    Celestino, Joseph
    Rangel, Kelly M.
    Badal, Sunil
    Pereira, Igor
    Ram, Prahlad T.
    Maxwell, George L.
    Eberlin, Livia S.
    Futreal, P. Andrew
    Bast, Robert C., Jr.
    Fleming, Nicole D.
    Conrads, Thomas P.
    Sood, Anil K.
    JAMA NETWORK OPEN, 2022, 5 (10) : E2236626
  • [33] In vivo tumor growth of high-grade serous ovarian cancer cell lines
    Mitra, Anirban K.
    Davis, David A.
    Tomar, Sunil
    Roy, Lynn
    Gurler, Hilal
    Xie, Jia
    Lantvit, Daniel D.
    Cardenas, Horacio
    Fang, Fang
    Liu, Yueying
    Loughran, Elizabeth
    Yang, Jing
    Stack, M. Sharon
    Emerson, Robert E.
    Dahl, Karen D. Cowden
    Barbolina, Maria V.
    Nephew, Kenneth P.
    Matei, Daniela
    Burdette, Joanna E.
    GYNECOLOGIC ONCOLOGY, 2015, 138 (02) : 372 - 377
  • [34] Phenotypic heterogeneity and instability of tumor-initiating cells in high-grade serous cancer
    Stewart, Jocelyn M.
    Shaw, Patricia A.
    Bernardini, Marcus Q.
    Ailles, Laurie E.
    Neei, Benjamin G.
    CANCER RESEARCH, 2012, 72
  • [35] Influence of p53 Isoform Expression on Survival in High-Grade Serous Ovarian Cancers
    Bischof, Katharina
    Knappskog, Stian
    Hjelle, Sigrun M.
    Stefansson, Ingunn
    Woie, Kathrine
    Salvesen, Helga B.
    Gjertsen, Bjorn T.
    Bjorge, Line
    SCIENTIFIC REPORTS, 2019, 9 (1)
  • [36] Clinical relevance of TP53 hotspot mutations in high-grade serous ovarian cancers
    Tuna, Musaffe
    Ju, Zhenlin
    Yoshihara, Kosuke
    Amos, Christopher I.
    Tanyi, Janos L.
    Mills, Gordon B.
    BRITISH JOURNAL OF CANCER, 2020, 122 (03) : 405 - 412
  • [37] The Changing View of High-Grade Serous Ovarian Cancer
    Berns, Els M. J. J.
    Bowtell, David D.
    CANCER RESEARCH, 2012, 72 (11) : 2701 - 2704
  • [38] Influence of p53 Isoform Expression on Survival in High-Grade Serous Ovarian Cancers
    Katharina Bischof
    Stian Knappskog
    Sigrun M. Hjelle
    Ingunn Stefansson
    Kathrine Woie
    Helga B. Salvesen
    Bjorn T. Gjertsen
    Line Bjorge
    Scientific Reports, 9
  • [39] Immune microenvironment composition in high-grade serous ovarian cancers based on BRCA mutational status
    Corvigno, Sara
    Burks, Jared K.
    Hu, Wei
    Zhong, Yanping
    Jennings, Nicholas B.
    Fleming, Nicole D.
    Westin, Shannon N.
    Fellman, Bryan
    Liu, Jinsong
    Sood, Anil K.
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2021, 147 (12) : 3545 - 3555
  • [40] Immune microenvironment composition in high-grade serous ovarian cancers based on BRCA mutational status
    Sara Corvigno
    Jared K. Burks
    Wei Hu
    Yanping Zhong
    Nicholas B. Jennings
    Nicole D. Fleming
    Shannon N. Westin
    Bryan Fellman
    Jinsong Liu
    Anil K. Sood
    Journal of Cancer Research and Clinical Oncology, 2021, 147 : 3545 - 3555